PMID-40956256 — AACE 2025 Clinical Practice Algorithm for Obesity

[DRAFT — authored 2026-04-18. Guideline reference.]

Citation

Mechanick JI, Apovian CM, Butsch WS, Hurley DL, McGowan BM, Reisin E, Shannon CM, Still CD, Tauqeer Z, Zilbermint M, on behalf of the American Association of Clinical Endocrinology. AACE 2025 Consensus Statement and Clinical Practice Algorithm on Obesity Pharmacotherapy. Endocr Pract. 2025;31(9):1045-1068. doi: 10.1016/j.eprac.2025.07.012. PMID: 40956256.

Scope

Comprehensive consensus statement from the American Association of Clinical Endocrinology (AACE) on pharmacotherapy for obesity in adults, with emphasis on stage-based treatment by weight-related complication (WRC) burden.

Framework

Adiposity-Based Chronic Disease (ABCD) Paradigm

AACE re-affirms its ABCD model: obesity is classified by both anthropometric stage (BMI/waist circumference) and complication stage (WRC severity). Pharmacotherapy decisions anchor to complication stage, not BMI alone.

Complication-Centric Treatment Intensity

Stage 0 (no WRC): Behavioral/lifestyle first; pharmacotherapy considered if BMI ≥30 and lifestyle insufficient.
Stage 1 (mild WRC — e.g., prediabetes, dyslipidemia): GLP-1 agonist (semaglutide 2.4 mg or tirzepatide 5-10 mg) recommended.
Stage 2 (moderate-severe WRC — T2D, CV disease, CKD, OSA, MASH): GLP-1 or GIP/GLP-1 dual agonist at higher effective dose (semaglutide 2.4-7.2 mg, tirzepatide 10-15 mg). Metabolic/bariatric surgery evaluation.

Key Recommendations

GLP-1 agents are first-line pharmacotherapy across complication stages; selection by predominant comorbidity:
- ASCVD → semaglutide or tirzepatide
- CKD → semaglutide
- PAD → semaglutide (per STRIDE)
- MASH → tirzepatide or semaglutide
- Sleep apnea → tirzepatide
Higher-dose escalation: Wegovy HD (7.2 mg) supported as option for additional weight loss when 2.4 mg inadequate after ≥4 weeks of tolerance.
Duration: Indefinite in most patients; regain expected on cessation.
Special populations:
- Adolescents 12-17 years with obesity + metabolic complication: GLP-1 agonists under specialty supervision.
- Elderly: Cautious dose titration; monitor for sarcopenia (lean-mass loss).
- Pregnancy: Discontinue pre-conception; teratogenicity data insufficient.
Emerging ocular safety consideration: NAION signal (EMA "very rare" classification 2025) warrants patient counseling; AACE recommends dialogue but does not yet recommend discontinuation based on this signal alone.

Pipeline Acknowledgment

Retatrutide (triple GLP-1/GIP/glucagon): Phase 3 TRIUMPH ongoing; AACE notes ~24% weight loss in Phase 2 data — "promising but pre-regulatory."
CagriSema: REDEFINE data being evaluated; AACE notes mixed REDEFINE-1 result and positive REDEFINE-2 superior-to-semaglutide result.
Orforglipron (oral non-peptide GLP-1 agonist): ATTAIN-1 supports oral non-peptide pathway.

Compounded Products

AACE explicitly opposes compounded GLP-1 use outside of documented patient-specific medical need (503A narrow-criteria).
Cites FDA alerts on dosing errors and lack of standardized quality.

Discontinuation & Monitoring

Weight regain pattern described; long-term adherence counseling critical.
Recommend baseline and periodic: renal function, thyroid (C-cell concern cite), HbA1c in T2D, lipid panel, mental-health screen.
Monitor for GI symptom tolerance and gallbladder symptoms.

Evidence Level

Level I (AACE grades) — consensus statement incorporating evidence-based systematic review.

Limitations (Author-acknowledged)

Most evidence from industry-sponsored RCTs.
Long-term (>5 year) outcome data still accumulating.
Head-to-head comparisons among GLP-1 agents and dual agonists limited.

Linked Peptides

Related References

Orchestrator Notes

Companion guideline to ADA Standards of Care; cite both where Module 5 content asserts "current consensus."
AACE complication-stage framework is a teaching anchor for Lesson 5.1 / 5.2.
Author list per published citation; verify any direct attribution at time of formal review.

PMID-40956256 – AACE 2025 Obesity Algorithm